Inactive Instrument

Senzime AB (publ) Share Price Nasdaq Stockholm

Equities

SE0002478776

Medical Equipment, Supplies & Distribution

Financials

Sales 2024 * 79.8M 7.38M 588M Sales 2025 * 198M 18.35M 1.46B Capitalization 879M 81.24M 6.47B
Net income 2024 * -106M -9.8M -781M Net income 2025 * -34M -3.14M -251M EV / Sales 2024 * 10.5 x
Net cash position 2024 * 42M 3.88M 309M Net cash position 2025 * 5M 462K 36.84M EV / Sales 2025 * 4.4 x
P/E ratio 2024 *
-8.25 x
P/E ratio 2025 *
-25.3 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 33.66%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Senzime AB (publ)

Managers TitleAgeSince
Chief Executive Officer 51 31/12/15
Director of Finance/CFO 54 31/12/21
Chief Tech/Sci/R&D Officer 48 31/12/19
Members of the board TitleAgeSince
Chief Executive Officer 51 31/12/15
Director/Board Member 71 31/12/22
Director/Board Member 70 31/12/21
More insiders
Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Calendar
More about the company